Pfizer gets new rebuff from UK cost body for cancer drug
NICE recommendations are preliminary and subject to further consultation.
Written by Reuters
London |
1 min read
Whatsapp
Twitter
Facebook
Reddit
Pfizer suffered a second rejection in two days from Britain’s health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
You have exhausted your monthly limit of free stories.
Read more stories for free with an Express account.
